/PRNewswire/ XNK Therapeutics AB ("XNK") today announced that the company s autologous natural killer (NK) cell therapy candidate XNK04 will be evaluated in.
/PRNewswire/ XNK Therapeutics today announced that it has been approved as an EU Tissue Establishment. This certificate allows the company to take control.
HUDDINGE, Sweden, April 3, 2023 /PRNewswire/ XNK Therapeutics today announced that it has been approved as an EU Tissue Establishment. This certificate allows the company to take control
/PRNewswire/ XNK Therapeutics today announced that it has received a GMP manufacturing license and a certificate of GMP compliance from the Swedish Medical.
HUDDINGE, Sweden, Feb. 21, 2023 /PRNewswire/ XNK Therapeutics AB's CEO Johan Liwing will present at Redeye's Regenerative Medicine/Cell Therapy event on February 22 between 09:00-12:00 CET. XNK's